Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Martin v. BioXcel Therapeutics, Inc. et al
Case Number:
3:23-cv-00915
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- Grant & Eisenhofer
- Hurwitz Sagarin
- Izard Kindall
- Jacobs & Dow
- Latham & Watkins
- Levi & Korsinsky
- Lowenstein Sandler
- Ment Law Group
- Mott Zezula
- Zeisler & Zeisler
Companies
Sectors & Industries:
-
February 09, 2024
AI Drugmaker Wants Investor Suit Over Botched Trial Tossed
Artificial intelligence-based drugmaker BioXcel Therapeutics Inc. is urging a Connecticut federal court to drop a suit accusing it of failing to disclose stumbles that allegedly affected the integrity of a dementia drug study, arguing it took necessary steps to inform the public and the government that the trial had been jeopardized.
-
October 06, 2023
2 Firms To Rep BioXcel Investors In Suit Against AI Drugmaker
Levi & Korsinsky LLP and Grant & Eisenhofer PA will co-lead a proposed shareholder class action in Connecticut alleging AI-based drugmaker BioXcel Therapeutics Inc. hurt investors after announcing plans to investigate results of a study of one of its drugs.
-
September 07, 2023
Attys Vie To Lead Investor Suit Against AI-Based Drugmaker
Seven legal teams have filed bids to represent a proposed class of investors in artificial intelligence-driven biopharmaceutical company BioXcel Therapeutics Inc. in a suit alleging that it hurt investors after announcing plans to investigate results of a study of one of its drugs.
-
July 10, 2023
AI-Based Pharma Co. Faces Investor Suit Over Study Woes
Artificial intelligence-driven biopharmaceutical company BioXcel Therapeutics Inc. has been hit with a proposed shareholder class action accusing the company of failing to disclose stumbles that allegedly affected the integrity of a study of a drug for agitated seniors with dementia.